The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter dose-finding study of irinotecan (CPT-11) based on UGT1A1 polymorphisms for metastatic colorectal cancer.
Hirohiko Sato
No relevant relationships to disclose
Mitsuo Shimada
Research Funding - Yakult Honsha
Nobuhiro Kurita
No relevant relationships to disclose
Takashi Iwata
No relevant relationships to disclose
Kozo Yoshikawa
No relevant relationships to disclose
Tomohiko Miyatani
No relevant relationships to disclose
Hideya Kashihara
No relevant relationships to disclose
Chie Mikami
No relevant relationships to disclose
Noriko Matsumoto
No relevant relationships to disclose